Hypoxia-regulated gene network in drug resistance and cancer progression

研究成果: Article

18 引文 (Scopus)

摘要

Hypoxia is a common phenomenon of solid tumors and contributes to aggressive phenotype and treatment failure. Hypoxia-inducible factor (HIF), a versatile transcription factor that regulates more than 5% of total human genes, not only plays important roles in controlling physiological processes, but is also a crucial mediator in hypoxia-induced tumor progression and chemoresistance. Overexpression of HIF-1α is detected in a wide spectrum of cancers via different kinds of mechanisms, including reduced oxygen concentration, loss-of-function of tumor suppressor gene, activating mutation of oncogenes, and hyperactivation of protein kinase signaling pathways. HIF-regulated genes involve in many pathological processes such as metabolic switch, drug efflux, angiogenesis, cell proliferation, and anti-apoptosis, which ultimately leads to increased tumor growth and drug resistance. Due to the common failure of classic chemotherapeutic agents in treating hypoxic cancers, novel strategies have been developed to target tumors under hypoxic conditions including inhibition of HIF activity and administration of bioreductive drugs. These new strategies may provide more effective and specific methods in targeting hypoxic tumors.

原文English
頁(從 - 到)779-792
頁數14
期刊Experimental Biology and Medicine
239
發行號7
DOIs
出版狀態Published - 2014 七月

指紋

Gene Regulatory Networks
Drug Resistance
Tumors
Genes
Pharmaceutical Preparations
Neoplasms
Physiological Phenomena
Hypoxia-Inducible Factor 1
Oncogene Proteins
Cell proliferation
Pathologic Processes
Tumor Suppressor Genes
Treatment Failure
Protein Kinases
Hypoxia
Transcription Factors
Switches
Cell Proliferation
Apoptosis
Oxygen

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

引用此文

@article{6da02c40e097470b8a78f4643e790d66,
title = "Hypoxia-regulated gene network in drug resistance and cancer progression",
abstract = "Hypoxia is a common phenomenon of solid tumors and contributes to aggressive phenotype and treatment failure. Hypoxia-inducible factor (HIF), a versatile transcription factor that regulates more than 5{\%} of total human genes, not only plays important roles in controlling physiological processes, but is also a crucial mediator in hypoxia-induced tumor progression and chemoresistance. Overexpression of HIF-1α is detected in a wide spectrum of cancers via different kinds of mechanisms, including reduced oxygen concentration, loss-of-function of tumor suppressor gene, activating mutation of oncogenes, and hyperactivation of protein kinase signaling pathways. HIF-regulated genes involve in many pathological processes such as metabolic switch, drug efflux, angiogenesis, cell proliferation, and anti-apoptosis, which ultimately leads to increased tumor growth and drug resistance. Due to the common failure of classic chemotherapeutic agents in treating hypoxic cancers, novel strategies have been developed to target tumors under hypoxic conditions including inhibition of HIF activity and administration of bioreductive drugs. These new strategies may provide more effective and specific methods in targeting hypoxic tumors.",
author = "Lin, {Shao Chieh} and Liao, {Wan Lin} and Lee, {Jenq Chang} and Tsai, {Shaw Jenq}",
year = "2014",
month = "7",
doi = "10.1177/1535370214532755",
language = "English",
volume = "239",
pages = "779--792",
journal = "Experimental Biology and Medicine",
issn = "1535-3702",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - Hypoxia-regulated gene network in drug resistance and cancer progression

AU - Lin, Shao Chieh

AU - Liao, Wan Lin

AU - Lee, Jenq Chang

AU - Tsai, Shaw Jenq

PY - 2014/7

Y1 - 2014/7

N2 - Hypoxia is a common phenomenon of solid tumors and contributes to aggressive phenotype and treatment failure. Hypoxia-inducible factor (HIF), a versatile transcription factor that regulates more than 5% of total human genes, not only plays important roles in controlling physiological processes, but is also a crucial mediator in hypoxia-induced tumor progression and chemoresistance. Overexpression of HIF-1α is detected in a wide spectrum of cancers via different kinds of mechanisms, including reduced oxygen concentration, loss-of-function of tumor suppressor gene, activating mutation of oncogenes, and hyperactivation of protein kinase signaling pathways. HIF-regulated genes involve in many pathological processes such as metabolic switch, drug efflux, angiogenesis, cell proliferation, and anti-apoptosis, which ultimately leads to increased tumor growth and drug resistance. Due to the common failure of classic chemotherapeutic agents in treating hypoxic cancers, novel strategies have been developed to target tumors under hypoxic conditions including inhibition of HIF activity and administration of bioreductive drugs. These new strategies may provide more effective and specific methods in targeting hypoxic tumors.

AB - Hypoxia is a common phenomenon of solid tumors and contributes to aggressive phenotype and treatment failure. Hypoxia-inducible factor (HIF), a versatile transcription factor that regulates more than 5% of total human genes, not only plays important roles in controlling physiological processes, but is also a crucial mediator in hypoxia-induced tumor progression and chemoresistance. Overexpression of HIF-1α is detected in a wide spectrum of cancers via different kinds of mechanisms, including reduced oxygen concentration, loss-of-function of tumor suppressor gene, activating mutation of oncogenes, and hyperactivation of protein kinase signaling pathways. HIF-regulated genes involve in many pathological processes such as metabolic switch, drug efflux, angiogenesis, cell proliferation, and anti-apoptosis, which ultimately leads to increased tumor growth and drug resistance. Due to the common failure of classic chemotherapeutic agents in treating hypoxic cancers, novel strategies have been developed to target tumors under hypoxic conditions including inhibition of HIF activity and administration of bioreductive drugs. These new strategies may provide more effective and specific methods in targeting hypoxic tumors.

UR - http://www.scopus.com/inward/record.url?scp=84904861737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904861737&partnerID=8YFLogxK

U2 - 10.1177/1535370214532755

DO - 10.1177/1535370214532755

M3 - Article

AN - SCOPUS:84904861737

VL - 239

SP - 779

EP - 792

JO - Experimental Biology and Medicine

JF - Experimental Biology and Medicine

SN - 1535-3702

IS - 7

ER -